Standard of Care Treatment: The Treat-to-Target Approach

Managing pediatric systemic lupus erythematosus (pSLE) has entered a new era. In 2023, updated recommendations from international rheumatology societies introduced a proactive, goal-oriented strategy ^[1].

The ‘Treat-to-Target’ (T2T) Strategy

The Treat-to-Target (T2T) approach means that instead of just reacting to symptoms as they appear, your child’s medical team sets clear, measurable goals for their health ^[1].

The primary objectives of T2T include:

• Clinical Remission: The ultimate goal is to have no detectable disease activity and no need for systemic corticosteroids ^[1].
• Low Disease Activity (LLDAS): If full remission is not immediately possible, the goal is “Lupus Low Disease Activity State,” where the disease is well-controlled with minimal symptoms and a very low dose of medication ^[1].
• Preventing Organ Damage: By keeping the disease quiet, the team aims to prevent permanent damage to organs like the kidneys, heart, and brain ^[1].

Crucial Safety Warning: Infection Risk

Important: Medications used to treat pSLE—including corticosteroids, mycophenolate mofetil (MMF), cyclophosphamide, and biologics—are immunosuppressants. They work by calming the overactive immune system, but this also means they reduce your child’s ability to fight off normal infections. A fever in an immunosuppressed child is a potential medical emergency. You must have a clear protocol from your doctor on what to do and who to call if your child develops a fever or signs of infection.

The Changing Role of Medications

The way doctors use medications has changed significantly to focus on effectiveness while minimizing long-term side effects.

The “Cornerstone” Medications

• Hydroxychloroquine: This is recommended for nearly every child with pSLE ^[1]. It helps prevent flares, protects the kidneys, and may improve long-term survival ^[2]. Note: Children on hydroxychloroquine require a baseline eye exam and regular ophthalmology follow-ups to monitor for rare but serious retinal toxicity ^[3].
• Mycophenolate Mofetil (MMF): Over the past decade, MMF has become a standard first-line treatment, especially for kidney involvement ^[2]. It is a powerful steroid-sparing agent, meaning it helps control the disease so that steroid doses can be reduced.

The Shift Away from Steroids

Corticosteroids (like prednisolone) are excellent at stopping a lupus flare quickly. However, they can interfere with a child’s growth, bone strength, and mood ^[1]. Current guidelines emphasize aggressive steroid-sparing—the goal is to taper the dose to the lowest effective level as quickly as possible ^[1].

Severe Disease and Biologic Therapies

When standard treatments aren’t enough to reach the target, doctors may use more potent therapies.

• Cyclophosphamide: While MMF has largely replaced it for long-term maintenance, this powerful immunosuppressant is still a standard “induction therapy” used initially for severe, organ-threatening pSLE ^[4].
• Belimumab: This is currently the only biologic medication specifically FDA-approved for children with pSLE. It targets specific immune cells and is often added to standard treatment to help lower disease activity and reduce steroid use ^[5].
• Rituximab: While technically “off-label” for pSLE, this medication is a vital “rescue therapy” for severe or refractory (difficult to treat) cases that do not respond to other drugs ^[6].

Why Consistency Matters

Reaching the “target” of remission requires time and consistent medication use. Because many lupus medications take weeks or even months to reach their full effect, staying the course—even when your child feels well—is the best way to prevent the “silent” inflammation that leads to future organ damage ^[1].